Health
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomized, double-blind, controlled, phase 3 trial – MD Linx
MDLinx original journal summary on Vaccines, Internal Medicine from The Lancet
Findings demonstrate the high efficacy of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG), in preventing laboratory-confirmed symptomatic COVID-19 disease in adults….
Continue Reading
-
Noosa News19 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General18 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News17 hours agoMurray Watt claims Queensland will follow Sussan Ley and ditch net zero by 2050
-
General16 hours agoRussian barrage kills 25 in Ukraine city as Zelenskyy holds talks with Turkish leader